Background: This randomized clinical trial was designed to evaluate the efficacy and safety of Tavipec® (Spicae aetheroleum), a phytomedicine obtained by steam distillation of the flowering tops of Lavandula latifolia, as compared to placebo in adult patients suffering from acute viral rhinosinusitis. Methodology: Patients with acute viral rhinosinusitis were randomly assigned to treatment with 2 capsules Tavipec® 150 mg or placebo thrice daily over a period of 7 days in a double-blind, parallel-group design. No additional treatment was admitted. The efficacy endpoints comprised the improvement of the main rhinosinusitis symptoms as per Major Symptom Score (MSS) and Sino-Nasal Outcome Test (SNOT-22) as well as of quality of life (QoL) by global assessment scale, evaluated at baseline, day 5 and day 8, respectively. Results: 288 patients were enrolled and randomized to treatment. At day 8 the patients in the Tavipec® group had a significantly lower MSS compared to placebo and the impact of rhinosinusitis symptoms on QoL was significantly reduced. A significantly higher proportion of Tavipec® treated patients experienced a change in SNOT-22 score ≥ 10 points at day 5 or day 8. No new safety signals were identified.
Introduction
Acute rhinosinusitis (ARS) is a respiratory disease with very high prevalence, thus constituting one of the most common reasons for which patients consult their general practitioner (GP). ARS in adults is characterized by inflammation of the paranasal sinuses and the nasal cavity with two or more symptoms, one of which should be either nasal blockage or nasal discharge; with or without facial pain/pressure and/or reduction or loss of smell, lasting for <12 weeks (1, 2) . With respect to healthcare systems ARS imposes a major socioeconomic burden both, in terms of direct expenses for outpatient visits, laboratory tests, antibiotic treatment failures, etc., and in terms of decreased productivity, reduced job effectiveness and impaired quality of life (QoL) (2) (3) (4) (5) .
Although approximately 98% of ARS are viral and self-limiting, antibiotics are often prescribed in primary care (1, (5) (6) (7) (8) (9) (10) (11) . In fact, only 0.5-2.0% of patients eventually develop acute bacterial rhinosinusitis (ABRS) secondary to a viral infection (1) . Consequently, viral ARS resolves without antibiotic treatment, which is also reflected in the current European guidelines, which recommend that the management of viral ARS should primarily rely on symptomatic treatment, i.e. the alleviation and reduction in duration of the clinical symptoms (1, 6, 7, 10) .
Herbal remedies are commonly and extensively used for symptomatic treatment of viral respiratory tract infections (RTIs) including viral ARS. Despite a growing body of evidence, the benefit of many herbal remedies still needs to be confirmed by more well-designed, double-blind, placebo-controlled, randomized clinical trials (RCTs) (1, 12) . Also, some herbal medicines have not been completely analysed in respect of the pharmacodynamic and pharmacokinetic properties of their active compound(s).
The anti-inflammatory properties and mode of action (MoA) of plant derived monoterpenes as well as their efficacy to control signs and symptoms of RTIs including viral ARS have been thoroughly investigated (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) . Monoterpenes are resorbed in the gastrointestinal tract and enter the circulation and reach the mucosal secretory glands, where they have secretolytic effects by enhancing mucus production and ciliary beat frequency (CBF) as well as stimulating ciliary cell differentiation, thus supporting the cleaning function and the recovery process of the mucosa (14, 15, 22, 30, 31) . Ciliary impairment and the disruption of the normal mucociliary flow have been demonstrated to be a feature of both viral ARS and ABRS (1, 8) .
Numerous pre-clinical trials have addressed the anti-inflammatory MoA of monoterpenes, i.e. linalool and/or cineol (13, 18, 29, (32) (33) (34) (35) whereas several RCTs have demonstrated their therapeutic benefits in inflammatory airway diseases (24-28, 36, 37) . Being rich in linalool and 1,8-cineole, Spicae aetheroleum is extensively used for its mucolytic, anti-inflammatory and spasmolytic activity (38, 39) . Recently, Kähler et al. demonstrated the efficacy and tolerability of Spicae aetheroleum (Tavipec®) for symptom relief in patients with acute bronchitis in a double-blind, placebo-controlled RCT (28) . However, equivalent data evaluating Tavipec® in the treatment of viral ARS are still lacking. The present doubleblind, placebo-controlled RCT was designed to fill this gap by assessing the efficacy and safety of Tavipec® in adult patients with viral ARS.
Materials and methods

Study subjects
Male and female outpatients aged ≥18 and ≤75 years with signs of viral ARS and a Major Symptom Score (MSS, composed of the five major symptoms nasal obstruction, rhinorrhoea, postnasal drip, sinus headache and facial pain) >5 but <12, a sublingual temperature <38,3°C, without dental involvement or need of antibiotic treatment at screening (baseline, visit 1, day 0) were included. Need for antibiotic treatment was defined as signs and symptoms suggestive of ABRS. According to EPOS criteria (1) , ABRS was assumed, if patients had at least 3 of the 5 symptoms purulent secretions, severe pain, fever >38°C, increased CRP (Creactive protein) or ESR (Erythrocytes sedimentation rate) and/ or double sickening. Enrolment was within 3 to (after study amendment) 5 days after the onset of the first symptoms (40) . Patients with signs or symptoms suggestive of ABRS, chronic (recurrent) rhinosinusitis as well as patients with nasal tumours or need/application of any concomitant local or systemic medications (e.g. antibiotics during the preceding 4 weeks, corticosteroids, antihistamines, immunosuppressive therapy at any time) were excluded or withdrawn from the study. To overcome a possible influence on the outcome of the study, apart from saline nasal douche / spray no other concomitant medications were allowed for symptom relief. If any other treatment than permitted by the study protocol was taken by the study participants, these treatments were recorded, and the study participants consequently excluded from the study due to protocol violations. Study participants were recruited by GPs or ear nose throat specialists at ten study centres located in Austria and Poland. The study was appro- Outcome Test (SNOT-22) questionnaire (40, 41) . A sum score was The global impact of disease on QoL was verbally assessed by patients via rating scale 0-10 ("not troublesome" to "worst thinkable troublesome"). Scores from 0-3, 4-7, and 8-10 indicated mild, moderate and severe impact, respectively. Adverse events were either reported by the patient and/or observed by the investigator. Safety assessments were performed at visit 2 and 3.
No interim analysis was planned or performed.
Statistical analyses
The sample size calculation was based on information from previous trials and considering the objectives of this trial (5, 26, 42) .
Since the efficacy variables were quantitative, but not necessarily normally distributed, a two-sided (α= 5%) Mann-Whitney test (rank-sum test) was applied to test the null hypothesis. For Figure 4 shows the results for the entire 22-item SNOT assessment and a detailed illustration of the individual scores for "sleep" (8 questions) and "nasal" symptoms (8 questions) at different treatment days according to the 4-subdomain structure as validated by Feng et al. (43) .
Results
Patient disposition
Safety evaluation
Nearly 90% of the patients in the Tavipec® (88.4%) and the placebo group (89.4%) were exposed to the allocated intervention for at least 6 days. A total of 39 adverse events (AEs)
were reported by 34 patients during the study ( Table 2 ). In the 
Discussion
Viral ARS is one of the most common reasons why patients seek medical advice in ambulatory care. Although clinical studies have demonstrated that antibiotics are not indicated for treatment of viral ARS, antibiotics are still prescribed at high rates while guideline-oriented management suggests symptomatic treatment and reassurance for patients with mild symptoms (1, (5) (6) (7) (8) (9) (10) . Herbal medicinal products containing plant-derived monoterpenes represent a well-tolerated therapeutic option for uncomplicated upper RTIs based on long-standing use, however, the evidence for beneficial effects of herbal compounds for the treatment of viral ARS is limited and there is a real need for more RCTs in this field (1) .
To the best of our knowledge this is the first placebo-controlled, multinational RCT evaluating the efficacy and safety of Tavipec® in adult patients with ARS. A 7-day treatment course with an oral dose of 300 mg Tavipec® three times daily led to a significant improvement of ARS symptoms by means of the MSS, the SNOT-22 and QoL assessment as compared to placebo. The dosage regimen was well tolerated; neither specific areas of concern nor new safety signals were identified during the study.
Our findings are in accordance with previously published RCTs that found good efficacy and safety of comparable monoterpenes in the treatment of ARS or uncomplicated upper RTIs, underlining their anti-inflammatory and secretolytic properties as mentioned above (24-28, 36, 37) . A recent review from Paparoupa and Gillissen highlighted the antioxidative, anti-inflammatory and antibacterial potential of a standardized combination of dlimonene, 1,8-cineole and alpha-pinene (Myrtol® standardized)
in several acute and chronic RTIs (27) . The authors concluded that this kind of medication should be initiated in several acute and chronic RTIs, especially in cases when bacterial infection is uncertain. Federspil et al. found out that Myrtol® standardized was significantly superior to placebo in the treatment of 330 patients with ARS (25) . In a double-blind, placebo-controlled RCT cineole was significantly more effective for timely treatment of nonpurulent rhinosinusitis in 150 patients (24) . To date, one placebocontrolled RCT examined the efficacy and safety of Tavipec® in acute RTIs: Kähler et al. administrated 300 mg Tavipec® three times daily to 256 patients with uncomplicated acute bronchitis (28) . The treatment with Tavipec® exhibited a significant mean difference of 25% of a defined total bronchitis severity score (BSS) between verum and placebo after 7 (p<0.005) and 10 days (p<0.009) of full medication as well as a significant amelioration of the patients' QoL (p<0.001) as compared to placebo.
In our study we focused on symptom relief and health-related QoL patterns by using the MSS, SNOT-22 and patients' verbally rated QoL as outcome measures. The MSS was explicitly designed to measure the severity of the most relevant rhinosinusitis symptoms and has been previously applied in numerous rhinosinusitis clinical trials in this field (5, 40, (44) (45) (46) . Our results revealed a significant improvement of the mean MSS in verum treated patients after 7 days of full medication (p<0.001), however, the initially aimed-for difference of 20% in the mean MSS between Tavipec® and placebo after both 4 and 7 days of full medication was not achieved. This may be due to the self-limiting nature of ARS attenuating the magnitude of treatment effects when compared against placebo within the given time frame. This could also reflect the fact that our study design included patients with mild symptoms (MSS >5 and <12). When we conducted a post-hoc sensitivity analysis that included only patients with a baseline MSS >6 (n=228) -excluding ten patients with milder symptoms at baseline -we found significant results with a 20% difference in the mean MSS between Tavipec® and placebo treated patients after 4 and 7 days of full medication (both p<0.001).
Other than that, the strikingly high scores for postnasal drip in the Tavipec® group might have adversely affected the total MSS. This may be due to the established MoA of monoterpenes, whose secretolytic properties based on the increase of mucus production and CBF of the nasal mucosa are mainly responsible for the desired treatment effect (14, 15, 22, 30, 31) .
Apart from the MSS, the significant drop of the mean SNOT-22 score by 37 score points in verum treated patients after a 7-day treatment course is particularly noteworthy. With 22 diseasespecific, health-related questions, the validated SNOT-22
questionnaire is widely used to evaluate the disease-related burden on patients suffering from chronic rhinosinusitis. The main advantage of the SNOT-score is the holistic assessment of the various symptom-dimensions of rhinosinusitis (41) . It has been used in previous trials in ARS, however not yet formally validated for ARS (45) . In a population with chronic rhinosinusitis, Data are presented as n with % reporting in parentheses. score in persons without chronic rhinosinusitis (47) . In our study the mean SNOT-22 score of Tavipec® vs. placebo-treated patients at EOT was 9.5 vs. 15 
Conclusion
The results of our study demonstrate that Tavipec® effectively reduces the symptoms associated with ARS in adult patients.
The treatment with Tavipec® provided a perceptible symptom relief and amelioration of health-related QoL thus constituting a feasible alternative to the prescription of antibiotics in a guideline-oriented management of ARS.
